

ASX Announcement

Capital Structure Update

6 February 2026 – Racura Oncology Limited (“Racura”) advises that on 21 November 2025, the Company issued 941,090 Racura Oncology ordinary shares (Shares) on the cashless exercise of 4,000,000 unlisted options with an exercise price of \$2.65 and expiring 29 November 2025 (Options) issued to Dr Daniel Tillett (Managing Director & Chief Executive Officer) and Mr Phillip Lynch (former Chief Executive Officer & Non-Executive Director).

The Options were issued to Dr Tillett and Mr Lynch under the Company’s Employee Securities Incentive Plan approved by shareholders at the 2018 Annual General Meeting (ASX Announcement: 27 November 2018) and were exercised into Shares using the cashless exercise facility under that Plan.

Due to an administrative oversight, an aggregate of 179,242 additional Shares were issued to Dr Tillett and Mr Lynch and recorded on the Company’s share register, rather than the intended number of 761,828 Shares.

The Company has placed a holding lock on these Shares and is proposing to conduct a selective buy back and cancellation of the Shares, subject to shareholder approval at the Company’s Annual General Meeting to be held later this year. The Company will continue to keep Shareholders informed in accordance with its continuous disclosure obligations.

-ENDS-

About Racura Oncology (ASX: RAC)

Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.

Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical program in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura Oncology has collaborated with Astex, Emory University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.



If you have any questions on this announcement, or any past Racura Oncology announcements please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@racuraoncology.com

Media contact:

Cherie Hartley +61 418 737 020
cherie.hartley@irdepartment.com.au